EMPA-REG OUTCOME: Consistent reduction in risk of cardiovascular outcomes and mortality with empagliflozin irrespective of sulphonylurea use at baseline

被引：0
|
作者：
Inzucchi, S. E. [1 ]
George, J. T. [2 ]
Fitchett, D. [3 ]
Mattheus, M. [2 ]
Janista, C. [2 ]
Zinman, B. [4 ]
机构：
[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] EMPA-REG OUTCOME: consistent reduction in risk of cardiovascular (CV) outcomes and mortality with empagliflozin (EMPA) irrespective of sulphonylurea (SU) use at baseline
    George, J. T.
    Inzucchi, S. E.
    Fitchett, D.
    Mattheus, M.
    Janista, C.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S425 - S426
  • [2] Empagliflozin and Microvascular Outcomes in EMPA-REG Outcome
    Wanner, Christoph
    Lee, Christopher
    Woerle, Hans J.
    Mattheus, Michaela
    Inzucchi, Silvio E.
    Zinman, Bernard
    DIABETES, 2016, 65 : A283 - A283
  • [3] Empagliflozin and microvascular outcomes in EMPA-REG OUTCOME
    Wanner, C.
    Lee, C.
    Woerle, H. -J.
    Mattheus, M.
    Inzucchi, S. E.
    Zinman, B.
    DIABETOLOGIA, 2016, 59 : S483 - S484
  • [4] EMPA-REGOUTCOME: empagliflozin (EMPA) reduced the risk of cardiovascular (CV) outcomes and mortality irrespective of metformin (MET) use at baseline
    Huettner, S.
    Zinman, B.
    Fitchett, D.
    Woo, V.
    Mattheus, M.
    Janista, C.
    George, J. T.
    Inzucchi, S. E.
    DIABETOLOGIA, 2017, 60 : S426 - S427
  • [5] Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME
    Inzucchi, S. E.
    Khunti, K.
    Fitchett, D. H.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Ofstad, A. P.
    Zinman, B.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 104
  • [6] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
    Fisher, Miles
    BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141
  • [7] EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction
    Aroda, Vanita R.
    Sabatine, Marc S.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 932 - 933
  • [8] EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
    Perkovic, Vlado
    Levin, Adeera
    Wheeler, David
    Koitka-Weber, Audrey
    Mattheus, Michaela
    George, Jyothis
    von Eynatten, Maximilian
    Wanner, Christoph
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 12 - 12
  • [9] Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    Zwiener, Isabella
    Kaspers, Stefan
    Clark, Douglas
    George, Jyothis T.
    Zinman, Bernard
    DIABETES CARE, 2019, 42 (04) : E53 - E55
  • [10] Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME
    Schnee, J.
    Inzucchi, S. E.
    Zinman, B.
    McGinniss, J.
    George, J. T.
    Fitchett, D.
    DIABETOLOGIA, 2017, 60 : S85 - S86
12345